Professional Documents
Culture Documents
Global CGM
Global CGM
The market for global continuous blood glucose monitoring (CGM) systems was valued at around USD 0.7
billion in 2015 and is expected to reach USD 3.3 billion by 2022, growing at a CAGR of around 24.4% during the
forecast period of 2016 to 2022. During the last four decades, there have been continuous advances in the
field of glucose monitoring, which have led to the development of highly evolved blood glucose meters,
include non-invasive glucose monitoring (NGM) devices and continuous blood glucose monitoring systems
(CGM). Glucose monitoring is an integral part of diabetes management, and the maintenance of physiological
blood glucose concentration is the only way for a diabetic to avoid life-threatening diabetic complications.
CGM systems have led to tremendous improvements in diabetic management, as shown by the significant
lowering of glycated hemoglobin (HbA1c) in adults with type I diabetes. Most of the CGMS have been
minimally-invasive, although the more recent ones are based on NGM techniques.
Diabetes disease is growing across the globe at an extraordinary pace and has become a serious health issue
during the last two decades. It is a major cause of mortality in the age group of 2079 years. Based on its
rapidly increasing incidence, it has been declared a global epidemic by the World Health Organization (WHO).
According to the International Diabetes Federation (IDF), the number of diabetic patients reached 415 million
in 2015 globally and is expected to reach around 642 million by 2040. According to the IDF, global healthcare
expenditures to treat diabetes and its complications was USD 673 billion in 2015, representing 12% of total
global healthcare expenditures and is expected to exceed USD 802 billion by 2040.
Companies profiled:
Dexcom
Medtronic
Abbott
C8 Medisensors
Integrity Applications Ltd.
OrSense Ltd.
Echo Therapeutics Inc.
Novo Nordisk, etc.
2 Executive summary
3 Qualitative analysis
6 Company profiles